Innovation immunomodulatory treatment case study of men diagnosed with relapsing-remitting multiple sclerosis (MS)
|
|
- Hector McLaughlin
- 5 years ago
- Views:
Transcription
1 Available online at WSN 78 (2017) EISSN Innovation immunomodulatory treatment case study of men diagnosed with relapsing-remitting multiple sclerosis (MS) Martyna Siudak 1,2, *, Dominika Cylke 2, Anna Tober-Marczewska 2 1 Department of Animal and Human Physiology, University of Gdansk, Gdansk, Poland 2 Students Scientific Society Homunculus, University of Gdansk, Gdansk, Poland martyna.siudak@phdstud.ug.edu.pl ABSTRACT Multiple Sclerosis (MS) is a complex disease that interferes with environmental factors and genetically predisposed conditions. This is a chronic, inflammatory disease of the central nervous system in which demyelination of neural tissue occurs. It is most often the case for young people with a slightly higher prevalence among women than men. Occurrence is rising in countries far from the equator, and the highest incidence is observed in temperate white people. This disease is characterized by so-called "rolls" that can last from 24 hours to several weeks. At this time there is a sudden increase in the existing symptoms or the appearance of a new one. The first signs of the disease are often mild and tend to cease quickly. The name reflects the spread of the pathological process in various places in the nervous system as well as the spread of changes over time. Regardless of the recognized form, the effect of MS is disability and reduced quality of life, which hinders self-reliance, self-care and freedom of movement. This paper is a case study of 49-year-old patient diagnosed with relapsingremitting MS included in the experimental program of immunomodulatory treatment. Keywords: sclerosis multiplex, SM, immunomodulatory, treatment, disability, experimental
2 1. INTRODUCTION Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system that results in demyelination of the nervous tissue. [1]. Described in 1868 by Jean-Martin Charcot. Mostly young people are sick - the peak occurs on the 20th - 40th year of life. Statistically 6 out of 10 cases are diagnosed among women [2]. In general, SM is a disease that damages the myelin sheath around nerve cells, which impairs the proper transmission of impulses along the nerve pathways in the brain and spinal cord. The name reflects the distribution of the pathological process at various points in the nervous system and the spread of time changes [3]. The occurrence of MS increases in countries far from the equator. The highest incidence was observed in white people living in temperate climates [4]. The disease is not considered to be hereditary, but there is evidence of genetic factors in the predisposition to disease [5]. Many researchers believe that the main role in the pathogenesis of MS play autoreactive T lymphocytes. In patients with acute attacks, autoreactive T lymphocytes were isolated that produced proinflammatory cytokines, while cell clones isolated during remission demonstrated increased production of anti-inflammatory cells. In patients with MS, cerebrovascular microcirculation was characterized by high expression of MHC II cells, which may lead to activation of autoreactive T lymphocytes [6] Symptoms SM is characterized by a series of intermediate symptoms. They are related to the disorder of the body function, which was responsible for the part of the brain that was damaged. This disease is characterized by so-called "rolls" that can last from 24 hours to several weeks. At this time there is a rapid increase in the existing symptoms or appearance of a new one. The first signs of the disease are often mild and tend to cease quickly. At first the disorder is poor and the patient rarely goes to the doctor [7]. In the further development of the disease the change arrives and more and more tissues are affected by dysfunction. Table 1. Symptoms due to occurrence [8]. Place of occurance Nervous and sensory system Symptoms Lhermitte`s symptom ("current propagates" along the spine); Imbalance, motor coordination disorder, loss of control of the limbs, paresis; dizziness, impaired concentration and logical thinking, short-term memory loss; changes in stimulus reception - decreased sensitivity to touch or hypersensitivity to heat, tingling sensation, numbness, hot flushes; slurred speech (dysarthria) - change of rhythm, speech slowed, slurred; blurred vision - strabismus, double or blurred vision, nystagmus, optic neuritis, pain on movement eyeball, blurred vision, difficulty in recognizing the color vision loss in one or both eyes -250-
3 Muscular system feeling of muscle weakness and real muscle weakness; paresis, spasticity with increased muscle tone, stiffness and muscle spasms; gait ataxia, difficulty in movement; muscle tension disorder; tremors and lack of body coordination Digestive system difficulty swallowing; dysfunction of intestinal function at the level of digestion and drainage Diagnosis SM may not present any symptoms for many years, so it is very difficult to recognize it at an early stage. In more than 25% of patients, the first symptom is deterioration or visual disturbance and a change in limb sensation. The first trigger of the disease, the most common is viral infection. The final diagnosis is made on the basis of visible changes in brain [9]. This involves, however, the advanced form of the disease. In order to differentiate a disease for multiple sclerosis, a person must have two cases of dementia associated with severe nerve conduction deterioration of at least 24 hours and the interval between them should not be less than 30 days. Clinical trials are then performed, the results of which are evaluated by McDonald's criteria. They analyze multiprocessing and time variations [10]. However, if the patient has gone through only one view of the disease, additional tests are needed. MS may present similar symptoms as other neurological or autoimmune diseases [11] Types MS may have different paths. Its definition is important, it differentiates treatment and also requires different diagnostics. In the United States in 1996, the National Multiple Sclerosis Society awarded four forms of MS: 1) relapsing-remitting - most common (80%); the earliest symptom is demyelinization of cells within the brain; there are distinguishable periods of illness and remission; 2) secondary progressive - permanent deterioration of health over the next 6 months; quickly leads to disability; occurs after years in more than half of patients with relapsing-remitting; 3) primary progressive - one of the rare (about 10%); usually recognized around the age of 40 or later; demyelinating changes mainly in the spinal cord; symptoms gradually worsen without violent exacerbations; 4) progressive-relapsing - the rarest and the heaviest; symptoms worsen gradually; often sudden deterioration occurs; no remission; symptoms persist and quality of life is not improved [3]. 2. EDSS SCALE The main tool for assessing the severity of symptoms and disability, also widely used in scientific research, is the Expanded Disability Status Scale (Figure 1). It is based on finding -251-
4 the presence of neurological symptoms on a scale of 1 to 9. The higher the scale, the higher the degree of disability of the patient [12]. Figure 1. Expanded Disability Status Scale (EDSS) [13]. 3. TREATMENT MS can be supported by therapies that allow to slow down the disease or recover lost nerve functions. Modifying therapies are used for this purpose, usually with the help of interferon derivatives, the human protein involved in the response of the immune system [14] EAE So far, no effective and no side effects of MS treatment have been lacking. A commonly used experimental model imitating SM is Experimental Autoimmune Encephalomyelitis (EAE), which can be caused by genetically predisposed mice, rats or rhesus monkeys [15]. Disease-specific Th1 CD4+ lymphocytes, that produce IFN-g, IL-2, TNF-b are responsible for the development of the disease. Th2 lymphocytes, CD8+ T lymphocytes, macrophages, B lymphocytes and possibly NK cells are also involved. EAE became possible to explore the complex interactions between cells of the immune system and the nervous system that underlie multiple sclerosis [16]. 4. CASE STUDY The patient, now a 49-year-old male, was diagnosed at age 35. The first symptoms occurred at the age of 20 and included optic neuritis. Probable cause of the first rolls of the disease was very strong stress and viral infection. On the day of diagnosis, EDSS disability was rated at 3, now it is 6 - the patient requires walking support
5 Relapses since 2004 occurred every two years, then every year. It is treated with Solu- Medrol. Doctors diagnosed relapsing-remitting form. The patient is receiving immunomodulatory treatment from January Every six months, in the form of infusion Ocrelizumab he takes Ocrelizumab mechanism of action It is a humanized CD20 protein-bound monoclonal antibody that is located on the surface of B lymphocytes at various stages of development leading to selective B cell death that expresses CD20. Its effects depend on the form of MS. It is believed that, in relapsingremitting about half the rolls becomes weaker or disappear. Patients with primaryprogressive - one third had a worsening condition, but after ocrelizumab, the patients were better at performing fitness tests and brain imaging studies. Like every medicine, ocrelizumab has side effects. Because it modifies the immune response, patients are more at risk for infectious diseases and some cancers. This is a breakthrough study showing a drug that slows the progression of primary-progressive type of MS. Although, the results are not fulfilling the dreams of patients and doctors, but it is still the first effective treatment [17]. 5. PROGNOSIS Prognosis in MS is various. It depends on the triggering factor, age, gender, race and timing of the diagnosis. The average life expectancy of people with MS is comparable to healthy, while dramatically change the quality of life [18]. Indicators of good prognosis are visual and sensory disturbances, while walking difficulties can herald a faster developing disease. Surprisingly, the hope is that the first symptoms are quickly resolved because they are characterized by rapid regression. If the patient complains only one symptom, it can also indicate a milder disease development. One third of the patients are able to work after years of illness and 15% will not experience the second rolls. Health deteriorates more rapidly in men, but they suffer less frequently. It is not possible to predict the exact course of MS, but the first five years of disease may suggest how it will behave in the individual case [19]. References [1] Rosati G., The prevalence of multiple sclerosis in the world: an update. Neurological Sciences 22, 2 (2001) [2] Amankwah N., Marrie R. Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts. Health Promot Chronic Dis Prev Can 37, 2 (2017) [3] Miller D., Barkhof F., Montalban X., Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet neurology 4, 5 (2005)
6 [4] Lassmann H. Experimental models of multiple sclerosis. Rev. Neurol. (Paris) 163, 6-7 (2007) [5] The International Multiple Sclerosis Genetics Consortium. Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study. N Engl J Med 357 (2007) [6] Rentzos M., Nikolaou C. Serum uric acid and multiple sclerosis. Clinical neurology and neurosurgery 108, 6 (2006) [7] Paty D. et al. MS COSTAR: a computerized patient record adapted for clinical research purposes. Annals of Neurology 36 (1994) [8] de Seze J., Zephir H., Hautecoeur P., Mackowiak A., Cabaret M., Vermersch P. Pathologic laughing and intractable hiccups can occur early in multiple sclerosis. Neurology 67, 9 (2006) [9] Confavreux C. Infections and the risk of relapse in multiple sclerosis. Brain 125, 5 (2002) [10] McDonald W., Compston A., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50, 1 (2000) [11] Polman Ch., Reingold S., et al. Diagnostic criteria for Multiple Sclerosis: 2005 revisions to the McDonald Criteria Ann Neurol 58 (2005) [12] Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 11 (1983) [13] Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) [14] Traynor K. Dalfampridine approved for MS. Am J Health Syst Pharm 67, 5 (2010) 335 [15] Sriram S., Steiner I. Experimental Allergic Encephalomyelitis: A misleading model of Multiple Sclerosis. Annals of Neurology 58 (2005) [16] Zipp F., Ellwardt E., Pramanik G., Mittmann T., Stroh A. Cortical Hyperactivity beyond the Immune Attack: Starting Point of Neurodegeneration. Neurology 86 (16 Supplement) (2016) [17] Montalban X., Hause S., Kappos L., et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376 (2017) [18] Weinshenker, B. Natural history of multiple sclerosis. Annals of Neurology 36 (Suppl) (1994) 6-11 [19] Pittock S., McClelland R., Mayr W., Jorgensen N., Weinshenker B., Noseworthy J., Rodriguez M. Clinical implications of benign multiple sclerosis: a 20-year populationbased follow-up study Ann Neurol 2, 56 (2004) ( Received 14 June 2017; accepted 10 July 2017 ) -254-
MEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease
MEDIA BACKGROUNDER Multiple Sclerosis: A serious and unpredictable neurological disease Multiple sclerosis (MS) is a complex chronic inflammatory disease of the central nervous system (CNS) that still
More informationWhat is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
More informationMultiple Sclerosis , The Patient Education Institute, Inc. nr Last reviewed: 04/17/2017 1
Multiple Sclerosis Introduction Multiple sclerosis, or MS, is a disease of the brain and spinal cord. Most patients with multiple sclerosis are able to lead a very functional life. However, MS causes a
More informationMultiple Sclerosis. Biology 12 Nervous System Project
Multiple Sclerosis Biology 12 Nervous System Project Overview Multiple Sclerosis (MS) is a progressive and unpredictable disorder that affects the central nervous system. Figure 1: The central nervous
More informationFrequently Asked Questions For persons with multiple sclerosis
Patient Education Frequently Asked Questions For persons with multiple sclerosis You may have many questions about the nature of multiple sclerosis (MS) and how it may affect you or your loved one. This
More informationMultiple Sclerosis. Brain Spinal Cord. Peripheral Nerves
Multiple Sclerosis Introduction Multiple sclerosis, or MS, is a disease of the brain and spinal cord. It affects about 400,000 Americans at any one time. Most patients with multiple sclerosis are able
More informationMultiple Sclerosis. By: Selena Fucci April 22, 2016
Multiple Sclerosis By: Selena Fucci April 22, 2016 Abstract: Multiple Sclerosis, MS, is a chronic neurological disorder in the brain and spinal cord involving inflammation and demyelination of the central
More informationORIGINAL CONTRIBUTION. Multiple Sclerosis That Is Progressive From the Time of Onset
ORIGINAL CONTRIBUTION Multiple Sclerosis That Is Progressive From the Time of Onset Clinical Characteristics and Progression of Disability P. B. Andersson, MBChB, DPhil; E. Waubant, MD; L. Gee, MPH; D.
More informationDOWNLOAD OR READ : MULTIPLE SCLEROSIS THE HISTORY OF A DISEASE PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : MULTIPLE SCLEROSIS THE HISTORY OF A DISEASE PDF EBOOK EPUB MOBI Page 1 Page 2 multiple sclerosis the history of a disease multiple sclerosis the history pdf multiple sclerosis the history
More informationGet on with life, we ll see you. in 6 months. Living your life your way with MS
Get on with life, we ll see you in 6 months. Living your life your way with MS If you re one of the 4000 New Zealanders affected by MS, ask your doctor or nurse if OCREVUS is right for you. Contents What
More informationResearch Article Optic Nerve and Spinal Cord Are the Major Lesions in Each Relapse of Japanese Multiple Sclerosis
International Scholarly Research Network ISRN Neurology Volume 211, Article ID 9476, 4 pages doi:1.542/211/9476 Research Article Optic Nerve and Spinal Cord Are the Major Lesions in Each Relapse of Japanese
More informationAutologous Hematopoietic Stem Cell Transplantation for the Treatment of Neuromyelitis Optica in Singapore
Case Reports 26 Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Neuromyelitis Optica in Singapore Koh Yeow Hoay, Pavanni Ratnagopal Abstract Introduction: Neuromyelitis optica (NMO)
More informationCNS pathology Third year medical students. Dr Heyam Awad 2018 Lecture 4: Myelin diseases of the CNS
CNS pathology Third year medical students Dr Heyam Awad 2018 Lecture 4: Myelin diseases of the CNS ILOS 1. to understand differences and similarities between diseases of myelin in CNS and PNS. 2. to understand
More informationInvestor Update. Downloads. Services PDF. Basel, 17 July 2017
Investor Update Basel, 17 July 2017 Roche s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and
More informationMULTIPLE SCLEROSIS INTRODUCTION OBJECTIVES. When the student has finished this module, he/she will be able to:
MULTIPLE SCLEROSIS INTRODUCTION Multiple sclerosis (MS) is a chronic disease of the nervous system. Multiple sclerosis causes inflammation and damage to the protective coatings in the brain and the nerves.
More informationNeurological Assessment for Multiple Sclerosis and Extended Disability Scale Score
Neurological Assessment for Multiple Sclerosis and Extended Disability Scale Score This section should only be completed by a neurologist or MD / ROD (Medical Doctor / Resident on Duty) involved in the
More informationBiologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS
Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS Disclosure Information Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS I have no financial
More informationVague Neurological Conditions
Vague Neurological Conditions Dr. John Lefebre, MD, FRCPC Chief Regional Medical Director Europe, India, South Africa, Middle East and Turkey Canada 2014 2 3 4 Agenda Dr. John Lefebre, M.D., FRCPC 1. TIA
More informationRoche s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis
Media Release Basel, 28 September 2017 Roche s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis OCREVUS is the first and only approved treatment
More informationUnderstanding your Tecfidera. treatment. Information for patients who have been prescribed treatment with Tecfidera.
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. Contents Treatment with Tecfidera About Multiple Sclerosis (MS) Multiple sclerosis A brief
More informationTECFIDERA (dimethyl fumarate) oral capsule
TECFIDERA (dimethyl fumarate) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationProgressive Multiple Sclerosis
Progressive Multiple Sclerosis Definitions, Clinical Course and Emerging Therapies M. Mateo Paz Soldán, MD, PhD Neurology Service, VA Salt Lake City HCS Assistant Professor of Neurology, University of
More informationThe Impact of Multiple Sclerosis in the. James Bowen, MD Multiple Sclerosis Center
The Impact of Multiple Sclerosis in the Pacific Northwest James Bowen, MD Multiple Sclerosis Center Swedish Neuroscience Institute Motor Symptoms of MS Weakness Spasticity - stiffness, brisk reflexes
More informationMultiple sclerosis. Tünde Csépány MD. PhD
Multiple sclerosis Tünde Csépány MD. PhD. 11. 19. 2008. Multiple Sclerosis Approximately 350 000 people in the United States are affected by MS Prevalence strongly dependent on latitude (25-224/100 000
More informationMultiple sclerosis. Tünde Csépány MD. PhD. 08. November 2017.
Multiple sclerosis Tünde Csépány MD. PhD. 08. November 2017. Multiple Sclerosis Approximately 350 000 people in the United States are affected by MS Prevalence strongly dependent on latitude (25-224/100
More informationMULTIPLE SCLEROSIS PROFILE
MULTIPLE SCLEROSIS PROFILE What is Multiple Sclerosis? Multiple sclerosis (MS) is a chronic, inflammatory disease of unknown etiology that involves an immune-mediated attack on the central nervous system
More informationMultiple sclerosis (MS) is a chronic autoimmune
Multiple sclerosis in older people Multiple sclerosis (MS) is the most common chronic disabling disease of the central nervous system in young adults. The late-onset MS (LOMS) variety, with clinical onset
More informationGILENYA (fingolimod) oral capsule
GILENYA (fingolimod) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationProgress in MS: Current and Emerging Therapies. Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada Today s Discussion Natural History and Classification of MS Treating MS Management
More informationDemyelinating Diseases: Multiple Sclerosis January 10, 2018 Dr. Ostrow
Demyelinating Diseases: Multiple Sclerosis January 10, 2018 Dr. Ostrow Reading: Robbins & Cotran, 9 th edition, pp 1283-1286 Robbins Basic Pathology, 9 th edition, 832-835 Overview: Grossly, myelin is
More informationMultiple Sclerosis (MS) is a
The role of interferon beta in multiple sclerosis management David J Rog MRCP, John P Mottershead MRCP, Greater Manchester Neurosciences Centre, Hope Hospital, Stott Lane, Manchester, M6 8HD SPL Multiple
More informationMedia Release. Basel, 10 November 2017
Media Release Basel, 10 November 2017 Roche s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis If approved, OCREVUS
More informationDOWNLOAD OR READ : MULTIPLE SCLEROSIS PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : MULTIPLE SCLEROSIS PDF EBOOK EPUB MOBI Page 1 Page 2 multiple sclerosis multiple sclerosis pdf multiple sclerosis Treatment. There is no cure for multiple sclerosis. Treatment typically
More informationWorksheet 3: Physician Medical Information Worksheet
Worksheet 3: Physician Medical Information Worksheet FOR PHYSICIAN USE The purpose of this worksheet is to assist you in supporting your patient s Social Security Disability Insurance application, in compiling
More informationBiology 3201 Nervous System # 7: Nervous System Disorders
Biology 3201 Nervous System # 7: Nervous System Disorders Alzheimer's Disease first identified by German physician, Alois Alzheimer, in 1906 most common neurodegenerative disease two thirds of cases of
More informationCentral nervous system
Central nervous system By Dr. Mohsen Dashti Clinical Medicine & Pathology 316 7 th Lecture Lecture outline Review of structure & function. Symptoms, signs & tests. Specific diseases. Review of structure
More informationEpidemiology, Diagnosis, Natural History & Clinical Course
Epidemiology, Diagnosis, Natural History & Clinical Course Multiple Sclerosis Immune-mediated, chronic, inflammatory disease precipitated by unknown environmental factors in genetically susceptible individuals
More informationDISORDERS OF THE NERVOUS SYSTEM
DISORDERS OF THE NERVOUS SYSTEM Bell Work What s your reaction time? Go to this website and check it out: https://www.justpark.com/creative/reaction-timetest/ Read the following brief article and summarize
More informationMedscape: What do you see as the main clinical implications of your results?
http://www.medscape.com/px/viewindex/more?bucket=columns§ionid=2011 Treatment Optimization for Multiple Sclerosis: An Expert Interview With Mark Freedman, MD Posted 11/10/2004 Editor's Note: Multiple
More informationRelapses Matter A GUIDE TO REPORTING MULTIPLE SCLEROSIS SYMPTOMS
Relapses Matter A GUIDE TO REPORTING MULTIPLE SCLEROSIS SYMPTOMS Scientific Review by: COLLEEN HARRIS, MN, NP, MSCN Nurse Practitioner/Coordinator University of Calgary MS Program Calgary, Alberta The
More informationPROCEEDINGS MULTIPLE SCLEROSIS: A PRIMER AND UPDATE * Ellen Whipple Guthrie, PharmD ABSTRACT
MULTIPLE SCLEROSIS: A PRIMER AND UPDATE * Ellen Whipple Guthrie, PharmD ABSTRACT Multiple sclerosis (MS) is a chronic neurologic disorder that is characterized by central nervous system inflammation, loss
More informationat least in part, by observing the effect of raising body temperature on the evoked potentials. upper limit of the normal value for latency of
Journal of Neurology, Neurosurgery, and Psychiatry, 1979, 42, 250-255 Effect of raising body temperature on visual and somatosensory evoked potentials in patients with multiple sclerosis W. B. MATTHEWS,
More informationChoices. Types of MS. Read me
Choices Types of MS Read me Types of MS Although multiple sclerosis affects individuals very differently, there are four broad groups into which MS is categorised. Clinically Isolated Syndrome Clinically
More informationHot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018
Hot Topics Multiple Sclerosis Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018 Disclosures Natalie Parks has received compensation from Biogen, EMD Serono, Roche, and Sanofi
More informationDOWNLOAD OR READ : MULTIPLE SCLEROSIS HOW I WON THE BATTLE PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : MULTIPLE SCLEROSIS HOW I WON THE BATTLE PDF EBOOK EPUB MOBI Page 1 Page 2 multiple sclerosis how i won the battle multiple sclerosis how i pdf multiple sclerosis how i won the battle
More informationPositive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Media Release Basel 21 December 2016 Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational
More informationGILENYA (fingolimod) oral capsule
GILENYA (fingolimod) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationMultiple Sclerosis Diagnosis And Therapy
Multiple Sclerosis Diagnosis And Therapy 1 / 6 2 / 6 3 / 6 Multiple Sclerosis Diagnosis And Therapy Treatment. There is no cure for multiple sclerosis. Treatment typically focuses on speeding recovery
More informationInternational Brain Bee Syllabus 2012 Department of Neurosciences, Universiti Sains Malaysia
BRAIN DEVELOPMENT The cells of the nervous system connect with one another in trillions of remarkably specific patterns that form and change over the course of an organism s life. These connections develop
More informationProf. Dimitrios Karussis Director of the Hadassah Center for MS
The Center for Multiple Sclerosis (MS) provides the patient a multidisciplinary approach for the management of the various problems related to MS and with the best available of experimental treatments
More informationAnalysis of prognostic significance of clinical and paraclinical indices in case of different types of acute disseminated encephalomyelitis course.
1 2 Analysis of prognostic significance of clinical and paraclinical indices in case of different types of acute disseminated encephalomyelitis course. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
More informationTHE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY
THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY John R. Rinker II, MD University of Alabama at Birmingham Birmingham VA Medical Center May 29, 2014 DISCLOSURES Salary/Research:
More informationAUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationCOPYRIGHT 2012 THE TRANSVERSE MYELITIS ASSOCIATION. ALL RIGHTS RESERVED
The Transverse Myelitis Association...advocating for those with acute disseminated encephalomyelitis, neuromyelitis optica, optic neuritis and transverse myelitis ACUTE DISSEMINATED ENCEPHALOMYELITIS (ADEM)
More informationP1: OTA/XYZ P2: ABC c01 BLBK231-Ginsberg December 23, :43 Printer Name: Yet to Come. Part 1. The Neurological Approach COPYRIGHTED MATERIAL
Part 1 The Neurological Approach COPYRIGHTED MATERIAL 1 2 Chapter 1 Neurological history-taking The diagnosis and management of diseases of the nervous system have been revolutionized in recent years by
More informationMedia Release. Basel 12 January 2018
Media Release Basel 12 January 2018 Roche s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis First and only approved
More informationTHE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY
THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY John R. Rinker, II, MD University of Alabama at Birmingham June 2, 2016 DISCLOSURES Research Support: Biogen Idec; Department of
More informationProblems of Neurological Function. Unit 10
Problems of Neurological Function Unit 10 Independent Student Review Brain Anatomy and physiology of cerebral hemispheres, diencephalon, brain stem, and cerebellum Meninges, ventricles, flow of CSF Blood
More informationMultiple Sclerosis. What types of MS are there? 4 There are 4 types of MS.
Multiple Sclerosis What is Multiple Sclerosis? 1,2 Multiple Sclerosis (MS) is a nervous system disease that affects the brain and spinal cord. The cause of MS is unknown. But, many investigators believe
More informationEpidemiology. Geographical distribution: Average onset age: years
Multiple sclerosis chronical disease, characterized by multiple areas of inflamation and demielination in the CNS One of the major causes of disability in the young adult Variable clinical picture and
More informationPATIENTS WITH MULTIPLE SCLEROSIS
3 PATIENTS WITH MULTIPLE SCLEROSIS PREFER EARLY DIAGNOSIS Abstract The new diagnostic criteria for multiple sclerosis (MS) allow for a definite diagnosis in earlier stages of disease. Yet, clinicians may
More informationAdv Pathophysiology Unit 2: Neuro Page 1 of 8
Adv Pathophysiology Unit 2: Neuro Page 1 of 8 Learning Objectives for this file: 1. Amaurosis fugax presentation & DDX 2. Clinical diagnostics 3. Case study & followup Adv Pathophysiology Unit 2: Neuro
More informationABSTRACT Background In patients with isolated syndromes that are clinically suggestive of multiple sclerosis,
A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS PETER A. BREX, M.D., OLGA CICCARELLI, M.D., JONATHON I. O RIORDAN, M.D., MICHAEL SAILER, M.D., ALAN J. THOMPSON, M.D.,
More informationMultiple Sclerosis. What is multiple sclerosis? What is the cause? What are the symptoms?
What is multiple sclerosis? Multiple Sclerosis Multiple sclerosis (MS) is a disease of the central nervous system (the brain and spinal cord). Many people with multiple sclerosis are only mildly affected
More informationVarious Types of Pain Defined
Various Types of Pain Defined Pain: The International Association for the Study of Pain describes pain as, An unpleasant sensory and emotional experience associated with actual or potential tissue damage,
More informationneurological rehabilitation multiple sclerosis
neurological rehabilitation multiple sclerosis www.cliniquevalmont.ch WHAT IS MULTIPLE SCLEROSIS? Multiple Sclerosis (MS) is an inflammatory disease which affects the central nervous system. This is characterised
More informationMULTIPLE SCLEROSIS - REVIEW AND UPDATE
MULTIPLE SCLEROSIS - REVIEW AND UPDATE Luka Vlahovic, MD Neuroimmunology/Multiple Sclerosis Creighton University Medical Center MS is primary demyelinating disease of the central nervous system. MS is
More informationDisclosures. Biogen Idec Novartis Acorda Genzyme Roche Pfizer
Disclosures Biogen Idec Novartis Acorda Genzyme Roche Pfizer Erik V Burton, M.D. Department of Neurology Multiple Sclerosis Specialty Clinic UNM Health Science Center Albuquerque, NM LIVING WITH MULTIPLE
More information3rd International Conference on Neurology & Therapeutics.
3rd International Conference on Neurology & Therapeutics www.neuroimmunology.ca Multiple sclerosis is a devastating disease The first description of the disease was mentioned in 14th century In 1838 Dr.
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org How
More informationMRI dynamics of brain and spinal cord in progressive multiple sclerosis
J7ournal of Neurology, Neurosurgery, and Psychiatry 1 996;60: 15-19 MRI dynamics of brain and spinal cord in progressive multiple sclerosis 1 5 D Kidd, J W Thorpe, B E Kendall, G J Barker, D H Miller,
More informationCommon Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases
Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases Case-Based Learning Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases Case-Based Learning Mayo Clinic College of
More informationPeripheral neuropathies, neuromuscular junction disorders, & CNS myelin diseases
Peripheral neuropathies, neuromuscular junction disorders, & CNS myelin diseases Peripheral neuropathies according to which part affected Axonal Demyelinating with axonal sparing Many times: mixed features
More informationMitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA Disclosures Consultant and Speaker Bureau member for Biogen-Idec, Pfizer, TEVA Neuroscience, Bayer, EMD Serrono, Questcor, Novartis,
More informationThe Nervous System. We have covered many different body systems which automatically control and regulate our bodies.
The Nervous System The Nervous System We have covered many different body systems which automatically control and regulate our bodies. There is one master system which controls all of these other systems.
More informationMovement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types
Background Movement Disorders Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Early Studies Found some patients with progressive weakness
More information387
http://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387! 388! http://my.fresnounified.org/personal/lygonza/gonzalez/neuron/neuron5synapse%20communication.png!! http://www.urbanchildinstitute.org/sites/all/files/databooks/2011/ch15fg25communication5between5neurons.jpg!!
More informationCertificate of Merit in Disorders of the Body Lesson 2: Epilepsy, Diabetes and Multiple Sclerosis
Certificate of Merit in Disorders of the Body Lesson 2: Epilepsy, Diabetes and Multiple Sclerosis Epilepsy Epilepsy is a condition in which there is a sudden burst of electrical energy in the brain, which
More informationCentral nervous system demyelinating diseases - Multiple sclerosis -
Central nervous system demyelinating diseases - Multiple sclerosis - Amilton Antunes Barreira Department of Neurology Faculdade de Medicina and Hospital das Clínicas de Ribeirão Preto - USP Diseases of
More informationMultiple sclerosis in Japan: Nationwide surveys over 30 years
Neurology Asia 28; 13 : 131 143 Multiple sclerosis in Japan: Nationwide surveys over 3 years Jun-ichi Kira, Takaaki Ishizu, Manabu Osoegawa, and The Research Committee of Neuroimmunological Diseases Department
More informationSocial relationships, knowledge and adjustment to multiple sclerosis
Journal of Neurology, Neurosurgery, and Psychiatry 1984;47: 372-376 Social relationships, knowledge and adjustment to multiple sclerosis CP MAYBURY,* CR BREWINt From the Department of Psychology, Clifton
More informationMUSCULOSKELETAL AND NEUROLOGICAL DISORDERS
MUSCULOSKELETAL AND NEUROLOGICAL DISORDERS There are a wide variety of Neurologic and Musculoskeletal disorders which can impact driving safety. Impairment may be the result of altered muscular, skeletal,
More informationChronic Inflammatory Demyelinating Polyneuropathy (C.I.D.P.)
University Teaching Trust Chronic Inflammatory Demyelinating Polyneuropathy (C.I.D.P.) Neurology 0161 206 2323 All Rights Reserved 2016. Document for issue as handout. Information about Chronic Inflammatory
More informationCarolyn Taylor, M.D. Swedish Neuroscience Center
Carolyn Taylor, M.D. Swedish Neuroscience Center When should disease modifying therapy be discontinued in MS? Should we be using aggressive treatments earlier in the MS disease course and reserving the
More informationWhile MS sometimes causes severe disability, it is only rarely fatal and most people with MS have a normal life expectancy.
Multiple sclerosis What is multiple sclerosis? Multiple sclerosis (MS) is a neuroinflammatory disease that affects myelin, a substance that makes up the membrane (called the myelin sheath) that wraps around
More informationDiagnostic Criteria, Clinical Courses, and Rating Scales in MS
Diagnostic Criteria, Clinical Courses, and Rating Scales in MS Introduction and Objectives Introduction This module will focus on diagnostic tools utilized in randomized clinical trials (RCTs) in MS. Diagnostic
More informationBRAIN STEM CASE HISTORIES CASE HISTORY VII
463 Brain stem Case history BRAIN STEM CASE HISTORIES CASE HISTORY VII A 60 year old man with hypertension wakes one morning with trouble walking. He is feeling dizzy and is sick to his stomach. His wife
More information2014 FLORIDA FOR THE TMA
Dear Corporate Sponsor, Celebrity and Supporter: We are proud to announce that we are hosting the 2nd Annual Central Florida Auction and Walk on December 12-13, 2014 in honor of our daughter Sarah Robbins
More informationSUSPECTED MECHANISMS INVOLVED IN MS AND PUTATIVE INTERACTIONS WITH HEPATITIS B VACCINE IN MS
SUSPECTED MECHANISMS INVOLVED IN MS AND PUTATIVE INTERACTIONS WITH HEPATITIS B VACCINE IN MS Emmanuelle Waubant, M.D. Olaf Stüve, M.D., PhD UCSF MS Center, San Francisco March 11, 2002 EPIDEMIOLOGY OF
More information1996 vs 2013 MS Phenotype Descriptions of Progressive Disease
Learning Objectives Upon completion, participants should be able to: Describe methods of distinguishing among RRMS, SPMS, and PPMS Incorporate available evidence about emerging and recently approved novel
More informationThe NIHSS score is 4 (considering 2 pts for the ataxia involving upper and lower limbs.
Neuroscience case 5 1. Speech comprehension, ability to speak, and word use were normal in Mr. Washburn, indicating that aphasia (cortical language problem) was not involved. However, he did have a problem
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 2, by the Massachusetts Medical Society VOLUME 343 N OVEMBER 16, 2 NUMBER 2 RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS CHRISTIAN CONFAVREUX,
More information1st interactive course in MS advanced managment
6-7 December - Toronto, Canada 1st interactive course in MS advanced managment IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Liesly Lee Sunnybrook Health Sciences Centre. Department
More informationNovel therapeutic modality of Apitherapy for controlling of Multiple Sclerosis
Novel therapeutic modality of Apitherapy for controlling of Multiple Sclerosis Ahmad G. Hegazi, Khaled Al- Menabbawy, Eman H. Abd El- Rahman and Suzette I. Helal National Research Center, Dokki, Giza,
More informationHISTORY TAKING ON NERVOUS SYSTEM. Dr. Amitesh Aggarwal
HISTORY TAKING ON NERVOUS SYSTEM Dr. Amitesh Aggarwal General points History of neurological symptoms should also be taken from patient and close relative or friend Memory loss, intoxication, aphasia Patient
More informationPROGRESSIVE MULTIPLE SCLEROSIS
page 1 / 5 page 2 / 5 progressive multiple sclerosis pdf Introduction. Multiple Sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disorder of the central nervous system (CNS)
More informationSpinal Cord Stimulation for Multiple Sclerosis and Spinal Cord Injury
Spinal Cord Stimulation for Multiple Sclerosis and Spinal Cord Injury R. Davis Neural Engineering Clinic, PO Box 480, Rockport, Maine, 04856, U.S.A. Introduction Since 1973, spinal cord stimulation (SCS)
More informationClinician s view of Benefit-Risk
Clinician s view of Benefit-Risk Gordon Francis, MD Novartis, Clinical Development Clinician s View of Benefit-Risk: a need for reliable metrics A tale of 3 drugs Natalizumab MS Crohn s Disease Fingolimod
More informationInherited erythromelalgia mutations in Na v 1.7
Inherited erythromelalgia mutations in Na v 1.7 I II III IV A863P N F216S S241T N395K L1 I848T L858F L858H L2 F1449V L3 C Mutation V 1/2 Activation V 1/2 Inactivation Slow Inactivation Deactivation Ramp
More informationParadoxical effects of temperature in multiple sclerosis
Journal of Neurology, Neurosurgery, and Psychiatry 1987;50:1 160-1164 Paradoxical effects of temperature in multiple sclerosis W P HONAN,*t J R HERON,*t D H FOSTER,t R S SNELGARt From the Department ofneurology,*
More information